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Abstract
This study aimed to investigate the incidence, predictors, and clinical outcomes of cardiac
tamponade after heart valve surgery. A total of 556 patients who underwent heart valve sur-
gery in a single tertiary center between January 2010 and March 2012 were studied. All
patients underwent transthoracic echocardiography (TTE) about 5 days after surgery and
TTE was repeated regularly. Patients with suspected acute pericardial hemorrhage were
excluded. Cardiac tamponade occurred in twenty-four (4.3%) patients and all underwent
surgical or percutaneous pericardial drainage. The median time of pericardial drainage after
surgery was 17 (interquartile range, IQR, 13–30) days. Infective endocarditis, mechanical
valve replacement of aortic or mitral valve, and any amount of pericardial effusion (PE) on
the first postoperative TTE were related to the occurrence of cardiac tamponade (all
p<0.05). After multivariate adjustment, occurrence of cardiac tamponade was associated
with any amount of PE on the first postoperative TTE (hazard ratio, HR, 14.00, p<0.001)
and mechanical valve replacement (HR 2.69, p = 0.025). The mean hospital days in patients
with cardiac tamponade was higher than those without (34.9 vs. 13.5, p = 0.031). After peri-
cardial drainage, there was no echocardiographic recurrence of significant PE during a
median of 34.8 (IQR 14.9–43.7) months after surgery. Cardiac tamponade after heart valve
surgery is not uncommon. Patients with any amount of PE at the first postoperative TTE or
mechanical valve replacement should receive higher attention with regard to the occurrence
of cardiac tamponade. Although it prolongs hospital stay, cardiac tamponade exhibits a
benign clinical course without recurrence after timely intervention.
Introduction
Pericardial effusion (PE) after cardiac surgery is a commonly encountered finding, even in
patients without evidence of postoperative pericardial hemorrhage. It is known to be related to
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an inflammatory process of the pericardium, called post-pericardiotomy syndrome (PPS) [1].
Although it mostly exhibits a benign course without clinically serious complications, it is able
to progress to potentially lethal cardiac tamponade which is associated with increased morbid-
ity and mortality [2–5]. A few studies demonstrated that postoperative PE or consequent con-
strictive physiology were prevalent in patients undergoing coronary artery bypass grafting
(CABG) [6,7]. However, there would be considerable variations in the incidence of PE and the
consequent clinical course according to the types of surgery, underlying diseases, or the use of
anticoagulants in patients undergoing heart valve surgery. Therefore, we sought to investigate
the incidence and clinical courses of PE and cardiac tamponade. Moreover, we tried to define
clinical or echocardiographic predictors of cardiac tamponade occurrence following heart
valve surgery.
Materials and Methods
The study consisted of a retrospective analysis of 556 consecutive adult patients who under-
went open heart surgery because of valvular heart disease from January 2010 through March
2012 at a single tertiary referral center. Medical records as well as serial echocardiographic
data following valvular heart surgery were reviewed. For all patients, the etiologies of valvular
heart disease, severities of valvular dysfunction, types of surgery (repair or replacement), and
concomitant surgery such as aorta surgery, CABG, or MAZE operation for atrial fibrillation
were reviewed. All the patients in this study underwent mandatory anticoagulation as recom-
mended by the guidelines, except for those with serious bleeding complications [8]. The length
of stay in hospital was calculated in each patient from valvular operation to discharge. The
patients were divided into two groups according to the occurrence of cardiac tamponade in
the post-operative period. Those patients with cardiac tamponade were further classified into
two subgroups based on the timing of its occurrence: early cardiac tamponade versus delayed
cardiac tamponade. Early cardiac tamponade was defined as cardiac tamponade occurring ear-
lier than 30 days after surgery. In contrast, delayed cardiac tamponade was defined as that
occurring 30 days or later after surgery.
The laboratory findings including cardiac biomarkers, inflammatory markers, and coagula-
tion profiles were reviewed in every patient. The peak values of post-operative white blood cell
count (WBC), creatine kinase (CK), CK-MB isoenzyme, C-reactive protein (CRP), activated
partial thromboplastin time (aPTT), and prothrombine time (PT) were analyzed. This study
was approved by the Institutional Review Board of Yonsei University, Severance Hospital,
Seoul, Korea. Written informed consent was exempt by the board as this study was retrospec-
tive in design. Patient records/information was anonymized and de-identified prior to
analysis.
All subjects underwent comprehensive transthoracic echocardiography (TTE) using com-
mercially available equipment prior to valvular heart surgery to assess the etiology of valvular
disease, severity of valvular dysfunction, and cardiac function. Standard two-dimensional and
Doppler measurements were performed per the recommendations of the American Society of
Echocardiography guidelines [9]. The first follow-up TTE after heart valve surgery was per-
formed on all patients at median 5 days (interquartile range, IQR, 4–7) after the surgery. Sub-
sequently, follow-up TTE was performed regularly or based on clinical decision. In general, if
the patients were uneventful, the second follow-up echocardiography was performed at 6
months after the surgery, and then annually for the evaluation of postoperative cardiac remod-
eling and serial follow-up of the valve function. However, if the patients exhibited uncertain
signs or symptoms, more frequent TTE follow-up was performed based on the clinician’s deci-
sion. PE was classified into three grades as follows: small, 10–14mm of loculated effusion or
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prothrombine time; TTE, trans-thoracic
echocardiography.
<10 mm of circumferential effusion; moderate, 15–19mm of loculated effusion or 10–14mm
of circumferential effusion; and large, any amount more than moderate effusion. This grade
was determined during the diastolic cardiac phase [10].
Cardiac tamponade was suspected in patients with otherwise unexplained tachycardia,
hypotension, or clinical signs including pulsus paradoxus, raised jugular venous pressure, and
cardiomegaly. The diagnosis was supported by following findings on echocardiography; right
or left atrial and ventricular collapse, inferior vena cava distension, and respiratory flow varia-
tion of mitral and tricuspid inflow velocities [10]. To exclude acute pericardial hemorrhage
related to bleeding complications immediately after surgery, ten patients (1.8%) who devel-
oped cardiac tamponade within 48 hours after surgery or continuous blood loss though peri-
cardial tube were excluded in the analysis.
Urgent interventions were conducted for every patient with cardiac tamponade following
the diagnosis. The selection of pericardial drainage method depended on the clinicians’ deci-
sion. In general, surgical drainage was preferred in patients with loculated PE or PE with poste-
rior-dominant location. Otherwise, percutaneous catheter drainage under echocardiographic
or fluoroscopic guidance was conducted.
Overall, the median follow-up duration was 34.8 months. The median time of pericardial
catheter drainage or surgical drainage following valvular surgery was evaluated. Readmission
or emergency department visit was counted only when requiring medical care from the
department of cardiology or cardiovascular surgery after discharge. Recurrence of PE was
defined when the development of a small or greater amount of effusion was identified on echo-
cardiography following drainage of PE during the follow-up period.
Continuous variables were presented as a mean ± standard deviation and categorical vari-
ables as absolute and relative frequencies (%). The differences between the two groups with or
without cardiac tamponade were analyzed using the Student t-test for continuous variables
and the Chi-square statistic for categorical variables. Univariate and multivariate Cox model
analyses were used to investigate the relationship between clinical, valvular, operative, or echo-
cardiographic characteristics, and the occurrence of cardiac tamponade. Univariate Cox
regression analysis was first performed with each variable and statistically significant variables
were selected (p<0.010). For multivariate Cox regression analysis, model 1 included infective
endocarditis, mechanical valve replacement, and concomitant MAZE procedure as covariates.
Then, any amount of PE on the first postoperative TTE was added in the final Cox regression
model (model 2). Cardiac tamponade-free survival rates were generated using Kaplan-Meier
curves and compared with the log-rank test according to the presence of infective endocarditis,
mechanical valves, concomitant MAZE procedure, or any amount of PE at the first postopera-
tive TTE. For all tests, statistical significance was set at p<0.05. All statistical analyses were per-
formed with SPSS version 21.0 (SPSS Inc., Chicago, Illinois).
Results
The baseline characteristics of all 556 patients and the two groups according to the occurrence
of cardiac tamponade are shown in Table 1. The mean age was 58.5 years, and 48.7% were
male. The numbers of patients with rheumatic valve disease, degenerative valve disease and
infective endocarditis as the etiology of valvular dysfunction were 167 (30.0%), 333 (59.9%),
and 44 (7.9%), respectively. Bicuspid aortic valve was surgically identified in 86 patients
(15.5%). Two hundred sixty-six (47.9%) patients had undergone valve replacement with a
mechanical prosthesis. Concomitant aorta surgery, CABG, and MAZE surgery were per-
formed in 58 (10.4%), 56 (10.1%) and 14 (2.5%) patients, respectively. There were no signifi-
cant differences in demographic characteristics, proportion of underlying valve function, or
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concomitant surgery between the two groups based on the occurrence of cardiac tamponade.
However, the prevalence of infective endocarditis as a reason for heart valve surgery was signif-
icantly higher in patients with cardiac tamponade than those without (20.8% vs. 7.3%,
P = 0.017). In terms of types of surgery, more patients in the cardiac tamponade group had
received mechanical valve replacement compared with the other group (66.7% vs. 46.1%,
P = 0.044).
Thirty-three patients (5.9%) exhibited PE at TTE performed at a median of 5 days following
heart valve surgery (Table 2, Fig 1). Twenty-four (4.3%) patients developed cardiac tamponade
Table 1. Characteristics of study population.
All (n = 556) Cardiac Tamponade
No (n = 532) Yes (n = 24)
Demographic characteristics
Age, years ± SD 58.5 ± 12.9 58.7 ± 12.9 54.3 ± 12.8
Male gender, n (%) 271 (48.7) 256 (48.1) 15 (62.5)
Body mass index, kg/m2 ± SD 23.2 ± 3.1 23.2 ± 3.2 23.2 ± 2.4
Prior history of valve operation, n (%) 41 (7.4) 41 (7.7) 0 (0)
Etiology of valvular disease
Rheumatic valve disease, n (%) 167 (30.0) 160 (30.1) 7 (29.2)
Degenerative valve disease, n (%) 225 (40.5) 219 (41.2) 6 (25.0)
Secondary valve disease, n (%) 13 (2.3) 13 (2.4) 0 (0.0)
Prosthetic valve failure, n (%) 21 (3.8) 21 (3.9) 0 (0.0)
Infective endocarditis, n (%) 44 (7.9) 39 (7.3) 5 (20.8)*
Bicuspid aortic valve, n (%) 86 (15.5) 80 (15.0) 6 (20.8)
Underlying valve function
Mitral regurgitation, n (%) 133 (23.9) 129 (24.2) 4 (16.7)
Mitral stenosis, n (%) 167 (30) 160 (30.1) 7 (29.2)
Aortic regurgitation, n (%) 67 (12.1) 64 (12) 3 (12.5)
Aortic stenosis, n (%) 130 (23.4) 125 (23.5) 5 (20.8)
Tricuspid regurgitation, n (%) 3 (0.5) 3 (0.6) 0 (0.0)
Types of surgery
Replacement with mechanical prosthesis 261 (46.9) 245 (46.1) 16 (66.7)*
Aortic valve, n (%) 157 (28.2) 146 (27.4) 11 (45.8)
Mitral valve, n (%) 146 (26.3) 137 (25.8) 9 (37.5)
Double valves, n (%) 49 (8.8) 45 (8.5) 4 (16.7)
Replacement with bioprosthesis 159 (28.6) 155 (29.1) 4 (16.7)
Aortic valve, n (%) 123 (22.1) 120 (22.6) 3 (12.5)
Mitral valve, n (%) 52 (9.4) 51 (9.6) 1 (4.2)
Double valves, n (%) 16 (2.9) 16 (3.0) 0 (0.0)
Repair
Aortic valve, n (%) 3 (0.5) 3 (0.6) 0 (0.0)
Mitral valve, n (%) 146 (26.3) 141 (26.5) 5 (20.8)
Concomitant surgery
Aorta surgery, n (%) 58 (10.4) 55 (10.3) 3 (12.5)
CABG, n (%) 56 (10.1) 55 (10.3) 1 (4.2)
MAZE operation, n (%) 14 (2.5) 12 (2.3) 2 (8.3)
* for p value < 0.05
CABG, coronary artery bypass grafting
doi:10.1371/journal.pone.0165754.t001
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Table 2. Echocardiographic and laboratory characteristics.
All (n = 556) Cardiac Tamponade
No (n = 532) Yes (n = 24)
Pericardial effusion
No (< small), n (%) 523 (94.1) 509 (95.7) 14 (58.4)
Any amount, n (%) 33 (5.9) 23 (4.3) 10 (41.7) *
Small, n (%) 17 (3.1) 12 (2.3) 5 (20.8)*
Moderate, n (%) 7 (1.2) 7 (1.3) 0 (0.0)
Large, n (%) 9 (1.6) 4 (0.7) 5 (20.8)*
Timing of cardiac tamponade
Early (< 30 days), n (%) 17 (3.1) 0 (0) 17 (70.8)
Delayed ( 30days), n (%) 7 (1.3) 0 (0) 7 (29.2)
Postoperative laboratory findings
WBC count, 109/mL 20.1 ± 7.3 20.2 ± 7.3 19.1 ± 7.2
CK-MB, IU/L 26.6 ± 22 26.2 ± 21.7 33.4 ± 26.9
CK, IU/L 621.5 ± 498.4 617.7 ± 499.6 692.9 ± 480.4
CRP, mg/L 90.8 ± 34 91.5 ± 33.9 78.5 ± 34.1
aPTT, sec 45.5 ± 15.7 45.5 ± 15.9 43.4 ± 13.6
PT, INR 1.83 ± 0.74 1.83 ± 0.75 1.71 ± 0.63
Number of patients receiving supra-therapeutic range of anticoagulation#, n (%) 23 (4.1) 23 (4.3) 0 (0.0)
* for P value < 0.05
#Supratherapeutic range of anticoagulation was defined as follows: aPTT > 80 seconds at post-operative 3day or PT > 4 INR at the day of the 1st post-
operative echocardiography.
WBC, white blood cell; CK, creatine kinase; CRP, C-reactive protein; aPTT, activated partial thromboplastin time; PT, prothrombin time; INR, international
normalized ratio
doi:10.1371/journal.pone.0165754.t002
Fig 1. Development and treatment of cardiac tamponade according to post-operative 5-day
pericardial effusion: Pericardial effusion was measured median 5-day after valvular surgery. Early
cardiac tamponade occurred within 30 days after surgery. Delayed tamponade was defined when it occurred
30days after surgery. Cardiac tamponade did not occur in patients with moderate PE at 5-day trans-thoracic
echocardiography.
doi:10.1371/journal.pone.0165754.g001
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on serial echocardiography. Among these, 17 patients experienced cardiac tamponade within
30 days following heart valve surgery, and 7 patients after 30 days. Furthermore, 29.4% (5/17)
of patients with small PE and 55.5% (5/9) patients with large PE at the first postoperative TTE
developed cardiac tamponade that required an urgent procedure. Among the 24 patients who
exhibited cardiac tamponade, 16 patients underwent pericardiocentesis and 8 patients received
surgical pericardiotomy. The median time of percutaneous or surgical pericardial drainage fol-
lowing heart valve surgery was 17 (IQR 13–30) days. There is no difference between groups
with and without cardiac tamponade in postoperative laboratory findings including inflamma-
tory markers, cardiac biomarkers, and coagulation profiles.
Table 3 shows the results from the Cox regression analyses. In univariate analysis, infective
endocarditis as the etiology of valve disease, mechanical valve replacement, and any amount of
PE at the first postoperative TTE were related to the occurrence of cardiac tamponade. A con-
comitant MAZE procedure showed marginal significance in univariate analysis. In multivari-
ate Cox regression model 1, not including postoperative TTE findings, the occurrence of
cardiac tamponade was associated with infective endocarditis (hazard ratio, HR, 3.21; confi-
dence interval, CI, 1.17–8.78, P = 0.023) and a concomitant MAZE procedure (HR 4.55; CI
1.05–19.71, P = 0.043). After including any amount of PE at the first postoperative TTE in
model 2, mechanical valve replacement (HR 2.69; CI 1.13–6.38, P = 0.025) and any amount of
PE (HR 14.00; CI 5.90–33.18, P<0.001) were independently related to the occurrence of car-
diac tamponade.
Kaplan-Meier curves for cardiac tamponade-free survival are depicted in Fig 2. Infective
endocarditis (P = 0.010), mechanical valve replacement (P = 0.042), and any amount of PE at
the first postoperative TTE (P<0.001) were associated with decreased cardiac tamponade-free
survival, and the cardiac tamponade mostly occurred within 30 days after heart valve surgery.
Concomitant MAZE procedure showed marginal statistical significance (P = 0.052) in cardiac
tamponade-free survival, and delayed cardiac tamponade also occurred even after 30 days
after surgery. The number of mean hospital days was higher in patients with cardiac tampo-
nade than in those without (34.9 vs. 13.5, P = 0.031). After pericardial drainage, there was no
echocardiographic recurrence of PE more than small amount during a median of 34.8 (IQR
14.9–43.7) months after surgery.
Discussion
The principal findings in the present study are that 1) the overall incidence of cardiac tampo-
nade was 4.3% after heart valve surgery; 2) the occurrence of cardiac tamponade was related
with infective endocarditis, valve replacement using mechanical valve, concomitant MAZE
procedure, and any amount of PE at the first postoperative TTE, which was performed about 5
days after surgery; 3) mechanical valve replacement and any amount of PE at the first postop-
erative TTE were independent predictors for the occurrence of cardiac tamponade; 4) cardiac
tamponade shows a benign clinical course without recurrence after timely intervention. The
results of our study indicate that patients with any amount of PE at the first postoperative TTE
or mechanical valve replacement should get more attention in the occurrence of cardiac tam-
ponade. In other words, patients without a mechanical valve and pericardial effusion at the
first postoperative TTE were less likely to experience cardiac tamponade in the postoperative
period.
The incidence of cardiac tamponade (4.3%) in this study was higher than those observed in
previous studies, which reported that only 0.8–0.9% patients experienced cardiac tamponade
after open heart surgery [2,10]. The present study included only patients undergoing heart
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valve surgery, which is associated with increased risk of PE and consequent cardiac tamponade
compared to CABG alone [2,3,10].
Although a few potential mechanisms have been suggested in previous studies, the exact
pathophysiology that results in postoperative PE or occurrence of cardiac tamponade is still
unclear. The results of this study yield some insight into the pathophysiology of postoperative
PE and consequent cardiac tamponade following heart valve surgery.
Table 3. Factors associated with postoperative cardiac tamponade.
Variable Univariate analysis Multivariate analysis
Model 1 Model 2
HR (95% CI) P value HR (95% CI) P value HR (95% CI) P value
Demographic characteristics
Age 0.98 (0.95 to 1.01) 0.111
Male gender 1.79 (0.78 to 4.01) 0.168
BMI 0.99 (0.87 to 1.13) 0.894
Valve characteristics
Infective endocarditis 3.38 (1.26 to 9.07) 0.015 3.21 (1.17 to 8.78) 0.023 2.26 (0.82 to 6.26) 0.116
Bicuspid aortic valve 1.80 (0.72 to 4.54) 0.212
Type of operation
Mechanical valve replacement 2.35 (1.01 to 5.50) 0.048 2.15 (0.91 to 5.07) 0.080 2.69 (1.13 to 6.38) 0.025
Concomitant MAZE 3.79 (0.89 to 16.13) 0.071 4.55 (1.05 to 19.71) 0.043 1.33 (0.29 to 6.20) 0.717
Postoperative PE
Any amount ( small) 13.96 (6.20 to 31.47) < 0.001 - - 14.00 (5.90 to 33.18) <0.001
doi:10.1371/journal.pone.0165754.t003
Fig 2. Kaplan-Meier curve for cardiac tamponade-free survival between groups with and without risk
factors (A: infective endocarditis, B: mechanical valve replacement, C: MAZE operation, D: Any
amount of pericardial effusion on the first postoperative echocardiography): Infective endocarditis,
mechanical valve replacement, and any amount of PE at the first postoperative TTE were associated
with decreased cardiac tamponade-free survival. Concomitant MAZE procedure showed marginal
statistical significance (P = 0.052) in cardiac tamponade-free survival, and delayed cardiac tamponade also
occurred even after 30 days after surgery.
doi:10.1371/journal.pone.0165754.g002
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First, Anticoagulation after heart valve surgery did not have obvious association with
increased risk of cardiac tamponade in this study, which has been considered a risk for cardiac
tamponade by promoting pericardial bleeding [2,10]. In this study, the levels of postoperative
anticoagulation including both aPTT and international normalized ratio (INR) in patients
with cardiac tamponade were not different from these values in patients without cardiac tam-
ponade. The exclusion of immediate cardiac tamponade occurring within 48 hours after sur-
gery, which is usually associated with pericardial bleeding, may influence the lack of the
association between anticoagulation and the occurrence of cardiac tamponade. Moreover,
since every patient received oral anticoagulants at least for 3 to 6 months after heart valve sur-
gery if there was no absolute contraindication, it was a challenge to prove the impact of antic-
oagulation on the occurrence of cardiac tamponade. However, the relationship between
mechanical valve replacement and cardiac tamponade might indicate an effect of anticoagula-
tion levels on the occurrence of cardiac tamponade.
Second, postoperative PE has been regarded as one of the major components of PPS, which
is characterized by lasting fever, pleuritic symptoms, and pericardial or pleural effusions fol-
lowing open heart surgery. Imazio et al. reported that PE was observed in about 90% of
patients with PPS [1]. Various studies have suggested that immunopathic mechanisms are the
most likely mechanism leading to the development of PPS [11,12]. Therefore, it is possible that
increased both local and systemic inflammation following surgery may play a role in the devel-
opment of PE and cardiac tamponade. Mechanical valves can promote both systemic and local
inflammation, represented by serum inflammatory markers such as IL-6 [13], and metallosis
of the adjacent tissue [14]. Infective endocarditis is undoubtedly proinflammatory in status
[15]. Previous studies demonstrated higher incidence, associated factors, and poor clinical out-
comes of PE in patients with infective endocarditis [16,17]. High titers of circulating immune
complexes in patients with infective endocarditis may aggravate PPS and result in cardiac tam-
ponade. A concomitant MAZE procedure also enhances local inflammation caused by either
surgical incision or the ablation itself [18]. Patients undergoing surgical or catheter ablation
for atrial fibrillation exhibited an inflammatory response after the procedure [19,20]. Further-
more, a recent worldwide survey on the efficacy and safety of catheter ablation for atrial fibril-
lation reported the occurrence of cardiac tamponade a median of 12 days following the
ablation procedure [21]. Thus, infective endocarditis and a concomitant MAZE procedure
may raise pericardial and systemic inflammation, which could mediate the relationship
between cardiac surgery and the development or worsening of PE.
The important role of postoperative TTE in screening the risk of cardiac tamponade after
heart valve surgery should be highlighted. In this study, the most powerful predictor for the
occurrence of cardiac tamponade was any amount of PE at the first postoperative TTE. There-
fore, postoperative TTE after heart valve surgery is very useful for the identification of patients
who are at risk of occurrence of cardiac tamponade and tailored frequent clinical or echocar-
diographic follow-up will be helpful for the early detection of, and timely intervention against,
cardiac tamponade. In particular, delayed cardiac tamponade may develop silently in the
absence of obvious clinical signs. Because it can be easily missed, and without early diagnosis
and treatment, can be life threatening, early decompression is required as soon as its presence
is confirmed [22,23]. Among the study population, there was no fatal event due to cardiac tam-
ponade following timely intervention.
Postoperative cardiac tamponade prolonged the patient’s hospital stay and was related to a
high rate of cardiovascular readmission. Postoperative constriction is associated with PE [6,7],
which can be associated with high readmission rate in patients with PE. Generally, however,
cardiac tamponade has a benign clinical course without recurrence following timely
intervention.
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To date, there is no obvious way to prevent cardiac tamponade following open heart sur-
gery. Erdil’s group suggested that posterior cardiotomy during valve replacement operation
might reduce the risk of cardiac tamponade, but they failed to show statistical significance in
their study [24]. Imazio et al. demonstrated that prophylactic colchicine could prevent incident
PE and the worsening of PE as well as PPS [25]. It might be particularly helpful to use prophy-
lactic colchicine for preventing cardiac tamponade in high-risk patients, such as those with
infective endocarditis or those with planned surgery involving a mechanical prosthesis or con-
comitant MAZE procedure. A prospective study is warranted to validate the benefit of preven-
tive medical treatment in patients at high risk of cardiac tamponade following heart valve
surgery.
Several limitations should be addressed in this study. First, regular echocardiographic fol-
low-up was not strictly followed, because of the retrospective nature of the study. It is possible
that some cases with PE were missed. Second, the incidence of cardiac tamponade in this
study was calculated after the exclusion of ten patients who had suspicious immediate post-
operative pericardial hemorrhage. The incidence of cardiac tamponade including immediate
bleeding seems to be a bit underestimated. Treatment of PE that was lower than the amount
that causes cardiac tamponade was different in each patient, and ranged from observation to
cessation of anticoagulation or adding anti-inflammatory medication. Finally, only C-reactive
protein was measured to represent systemic inflammatory reaction, which could be subopti-
mal to demonstrate systemic inflammation.
Conclusions
Cardiac tamponade is more common in patients with any amount of PE on the first postopera-
tive echocardiography after valvular heart surgery or mechanical valve replacement. Although
postoperative cardiac tamponade prolongs hospital stay and requires more readmission com-
pared with those without, it has a benign clinical course without recurrence following timely
intervention.
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